New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
07:01 EDTMYGNMyriad Genetics outlook still positive, says Cantor
After a judge denied Myriad's request for a preliminary injunction against a competitor and Myriad's stock decline more than 8% yesterday, Cantor says it expected the motion to be denied. The firm continues to believe that Myriad's position in the hereditary cancer testing market is strong, and it reiterates a $42 price target and Buy rating on the shares.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
06:40 EDTMYGNStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information
April 11, 2015
14:20 EDTMYGNWilliam Blair diagnostic services analyst holds analyst/industry conference call
Analysts, along with Dr. Todd Cohen, provide an industry update on an Analyst/Industry conference call to be held on April 16 at 3 pm.
April 8, 2015
08:45 EDTMYGNLife Sciences group well positioned heading into Q1 earnings, says Cowen
Cowen said the Life Sciences sector looks well positioned heading into Q1 earnings despite the group outperforming the broader market recently. The firm believes headwinds have intensified and multiples have stretched, but they see the downside risk as limited with upside risk dependent on improving end-market commentary, new products and milestones, and new details on capital deployment. Stocks in the space include Affymetrix (AFFX), Fluidigm (FLDM), GenMark (GNMK), Myriad Genetics (MYGN) and Quidel (QDEL).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use